All-in-one CRISPR/Cas-engineered glucocorticoid-receptor knock-out EBV-gp350-CAR knock-in T cells are potent and resistant to dexamethasone

Abstract Background Epstein-Barr virus (EBV) reactivation in immunocompromised patients and post-transplantation is associated with morbidity, mortality and with the onset of a variety of malignant diseases. Adoptive T-cell therapies have emerged as promising therapeutic options, but post-transplant...

Full description

Bibliographic Details

Published in:	Experimental Hematology & Oncology
Main Authors:	Theresa Kaeuferle, Maximilian Zwermann, Nadine Stoll, Paulina Ferrada-Ernst, Lena Jablonowski, Reinhard Zeidler, Semjon Willier, Dana Stenger, Abdallah Yassin, Renata Stripecke, Tobias Feuchtinger
Format:	Article
Language:	English
Published:	BMC 2025-03-01
Subjects:	CAR T cells EBV CRISPR/Cas Genetic engineering Adoptive T cell transfer Dexamethasone
Online Access:	https://doi.org/10.1186/s40164-025-00631-w